Antifungal Drug Resistance in Histoplasmosis

[1]  L. Wheat,et al.  Pulmonary Histoplasmosis Syndromes: Recognition, Diagnosis, and Management , 2004, Seminars in respiratory and critical care medicine.

[2]  K. Wood,et al.  Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy , 2003 .

[3]  A. Casadevall,et al.  Melanization of Cryptococcus neoformans and Histoplasma capsulatum Reduces Their Susceptibilities to Amphotericin B and Caspofungin , 2002, Antimicrobial Agents and Chemotherapy.

[4]  A. Casadevall,et al.  Histoplasma capsulatum Synthesizes Melanin-Like Pigments In Vitro and during Mammalian Infection , 2002, Infection and Immunity.

[5]  D. Bamberger,et al.  Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS , 2002, Annals of Internal Medicine.

[6]  L. Wheat,et al.  Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. , 2002, The Journal of infectious diseases.

[7]  R. Hafner,et al.  Antigen Clearance during Treatment of Disseminated Histoplasmosis with Itraconazole versus Fluconazole in Patients with AIDS , 2002, Antimicrobial Agents and Chemotherapy.

[8]  R. Hafner,et al.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  T. Davis,et al.  Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus Itraconazole , 2001, Antimicrobial Agents and Chemotherapy.

[10]  Newman Sl.  Cell-mediated immunity to Histoplasma capsulatum. , 2001 .

[11]  R. Hajjeh,et al.  The epidemiology of histoplasmosis: a review. , 2001, Seminars in respiratory infections.

[12]  D. Loebenberg,et al.  Comparison of a New Triazole, Posaconazole, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in Immunocompromised Mice , 2000, Antimicrobial Agents and Chemotherapy.

[13]  L. Wheat,et al.  Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. , 2000, The Journal of infectious diseases.

[14]  L. Wheat,et al.  Comparison of the Echinocandin Caspofungin with Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in a Murine Model , 2000, Antimicrobial Agents and Chemotherapy.

[15]  E. Brizendine,et al.  Comparison of Nikkomycin Z with Amphotericin B and Itraconazole for Treatment of Histoplasmosis in a Murine Model , 2000, Antimicrobial Agents and Chemotherapy.

[16]  M. Mcginnis,et al.  In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis,Coccidioides immitis, and Histoplasma capsulatum , 2000, Antimicrobial Agents and Chemotherapy.

[17]  D. Loebenberg,et al.  Comparison of a New Triazole Antifungal Agent, Schering 56592, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis in Immunocompetent Mice , 1999, Antimicrobial Agents and Chemotherapy.

[18]  A. Espinel-Ingroff.  Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts , 1998, Journal of Clinical Microbiology.

[19]  J. Graybill,et al.  Efficacy of Nikkomycin Z in the Treatment of Murine Histoplasmosis , 1998, Antimicrobial Agents and Chemotherapy.

[20]  J. Graybill,et al.  Treatment of Histoplasmosis with MK-991 (L-743,872) , 1998, Antimicrobial Agents and Chemotherapy.

[21]  M. Saag,et al.  Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. , 1997, The American journal of medicine.

[22]  P. Marichal,et al.  Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum , 1997, Antimicrobial agents and chemotherapy.

[23]  J. Wheat.  Histoplasmosis in the acquired immunodeficiency syndrome. , 1996, Current topics in medical mycology.

[24]  G. Cloud,et al.  Fluconazole Therapy for Histoplasmosis , 1996 .

[25]  F. Hecht,et al.  Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. , 1995, The American journal of medicine.

[26]  M. Saag,et al.  Itraconazole therapy for blastomycosis and histoplasmosis , 1992 .

[27]  B. Zimmer,et al.  Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis , 1990, Antimicrobial Agents and Chemotherapy.

[28]  T. Slama.  Treatment of disseminated and progressive cavitary histoplasmosis with ketoconazole. , 1983, The American journal of medicine.

[29]  M. Furcolow.  Comparison of Treated and Untreated Severe Histoplasmosis: A Communicable Disease Center Cooperative Mycoses Study , 1963 .

[30]  W. D. Kelly,et al.  The effect of sympathectomy on blood flow to bone. , 1963, JAMA.

[31]  M. Furcolow.  Comparison of treated and untreated severe histoplasmosis. , 1963 .